These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28213939)

  • 1. Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration.
    Negm OH; MacKenzie B; Hamed MR; Ahmad OAJ; Shone CC; Humphreys DP; Ravi Acharya K; Loscher CE; Marszalowska I; Lynch M; Wilcox MH; Monaghan TM
    Clin Exp Immunol; 2017 Jun; 188(3):437-443. PubMed ID: 28213939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.
    Abougergi MS; Kwon JH
    Dig Dis Sci; 2011 Jan; 56(1):19-26. PubMed ID: 20924675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection.
    Negm OH; Hamed M; Monaghan TM
    J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.
    Gilbert J; Leslie J; Putler R; Weiner S; Standke A; Penkevich A; Keidan M; Young VB; Rao K
    Anaerobe; 2021 Feb; 67():102299. PubMed ID: 33227427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
    Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
    J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.
    Salcedo J; Keates S; Pothoulakis C; Warny M; Castagliuolo I; LaMont JT; Kelly CP
    Gut; 1997 Sep; 41(3):366-70. PubMed ID: 9378393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
    Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
    Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).
    Leav BA; Blair B; Leney M; Knauber M; Reilly C; Lowy I; Gerding DN; Kelly CP; Katchar K; Baxter R; Ambrosino D; Molrine D
    Vaccine; 2010 Jan; 28(4):965-9. PubMed ID: 19941990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.
    Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H
    J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antitoxin responses in Clostridium-difficile-infected patients compared to healthy blood donors.
    von Eichel-Streiber A; Paik W; Knight K; Gisch K; Nadjafi K; Decker C; Bosnjak O; Cheknis A; Johnson S; von Eichel-Streiber C
    Anaerobe; 2016 Oct; 41():91-103. PubMed ID: 27427464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
    Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
    BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.
    Roberts A; McGlashan J; Al-Abdulla I; Ling R; Denton H; Green S; Coxon R; Landon J; Shone C
    Infect Immun; 2012 Feb; 80(2):875-82. PubMed ID: 22144483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
    Villafuerte Gálvez JA; Kelly CP
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of existing total anti-toxin B IgG immunity in outcomes of recurrent Clostridioides difficile infection.
    Rigo I; Young MK; Abhyankar MM; Xu F; Ramakrishnan G; Naz F; Madden GR; Petri WA
    Anaerobe; 2024 Jun; 87():102842. PubMed ID: 38552897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and optimization of a novel assay to measure neutralizing antibodies against Clostridium difficile toxins.
    Xie J; Zorman J; Indrawati L; Horton M; Soring K; Antonello JM; Zhang Y; Secore S; Miezeiewski M; Wang S; Kanavage AD; Skinner JM; Rogers I; Bodmer JL; Heinrichs JH
    Clin Vaccine Immunol; 2013 Apr; 20(4):517-25. PubMed ID: 23389929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review.
    O'Horo J; Safdar N
    Int J Infect Dis; 2009 Nov; 13(6):663-7. PubMed ID: 19186089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
    Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
    Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
    Monaghan TM; Robins A; Knox A; Sewell HF; Mahida YR
    PLoS One; 2013; 8(9):e74452. PubMed ID: 24058568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.